Recro Pharma Inc. (Nasdaq: REPH) reported positive results from a Phase III clinical trial of its intravenous acute postoperative pain treatment meloxicam sending the stock price up $1.54 to close at $9.30.
Recro Pharma reports upbeat study results
November 28, 2016 at 16:28 PM EST
